|
|
 |
| OVERVIEW |
| |
|
NYC Bioscience Bulletin provides the latest news and information on the thriving bioscience cluster in New York City. Several major funding agreements highlight this month�s issue.
Visit www.nycbiotech.org or contact us for more information on how New York City Economic Development Corporation can assist your business. |
|
| IN THE NEWS |
| |
|
Lev Pharmaceuticals Completes $35 Million Offering
New York City based Lev Pharmaceuticals, Inc. recently raised $35 million, in addition to a $21 million private placement raised by the company last year. Most recently, Lev announced positive results from a Phase II Trial of Cinryze in patients with acute attacks of hereditary angioedema. |
| Top ^ |
 |
|
Advanced BioHealing Raises $25 Million
Advanced BioHealing, Inc., with R&D offices in New York City, announced a $25.5 million raise in a Series C round of financing. Advanced BioHealing is an industry leader in the science of regenerative medicine, focusing on the commercialization of cell-based and tissue-engineered products. Two of the company�s products, Dermagraft, and TransCyte, have FDA approval for marketing. |
| Top ^ |
|
|
INNOVIVE Pharmaceuticals Closes $15 Million Equity Financing
New York City based INNOVIVE Pharmaceuticals, Inc. has closed a private placement offering of $15 million with Paramount BioCapital Inc. serving as the sole placement agent. INNOVIVE acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. |
| Top ^ |
|
|
Nephros Raises $12.7 Million in New Financing
Nephros, Inc., a medical device company with U.S. headquarters in New York City, recently raised $12.7 million in financing. In October, the company began a pivotal human clinical trial for two of its medical devices at Columbia University, with additional patients being treated at Albert Einstein College of Medicine in the Bronx. |
| Top ^ |
|
|
Callisto Pharmaceuticals Raises $11.2 Million
New York City based Callisto Pharmaceuticals, Inc., announced a private placement B round of $11.2 million. Callisto's drug candidates include two anti-cancer agents as well as a drug for gastrointestinal disorders. Atiprimod, its lead drug candidate, is currently in a Phase II clinical trial in advanced carcinoid cancer patients. |
| Top ^ |
|
|
Genzyme Acquires Bioenvision for $345 Million
New York City based Bioenvision, Inc. recently announced its acquisition by Genzyme Corporation. The merger will accelerate the clinical research of Clofarabine as a treatment for acute leukemia and will allow access to Clofarabine for physicians and patients in Genzyme�s distribution network. |
| Top ^ |
|
|
NANIRX Relocates from New Jersey to New York City
NANIRX has relocated its operations to the Audubon Business and Technology Center at Columbia University Medical Center. NANIRX is an early-stage, biopharmaceutical company focused on developing technology to enhance the efficacy of existing monoclonal antibody drugs. The company�s core technology is based on twenty-five years of research by Dr. David Cohen, of the NIH HIV vaccine development committee. |
| Top ^ | |
|